Diffusion weighted imaging in predicting progression free survival in patients with squamous cell carcinomas of the head and neck treated with induction chemotherapy

Academic Radiology

Volumn 18, Issue 10, 2011, Pages 1225-1232

  Berrak, Su ^a,b   Chawla, Sanjeev ^a   Kim, Sungheon ^a,c   Quon, Harry ^a   Sherman, Eric ^a,d   Loevner, Laurie A ^a   Poptani, Harish ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b MONMOUTH MEDICAL CENTER   (United States)

^c NEW YORK UNIVERSITY   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Apparent diffusion coefficient; Diffusion weighted MRI; Head and neck cancer; Induction chemotherapy; Squamous cell carcinoma; Survival

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; FLUOROURACIL; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CERVICAL LYMPH NODE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; HYPOPHARYNX CARCINOMA; INDUCTION CHEMOTHERAPY; LYMPH NODE METASTASIS; MALE; NASOPHARYNX CARCINOMA; OROPHARYNX CARCINOMA; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SQUAMOUS CELL CARCINOMA; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CONTRAST MEDIA; DIFFUSION MAGNETIC RESONANCE IMAGING; DISEASE PROGRESSION; FEMALE; GADOLINIUM DTPA; HEAD AND NECK NEOPLASMS; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 80052356892     PISSN: 10766332     EISSN: 18784046     Source Type: Journal    
DOI: 10.1016/j.acra.2011.06.009     Document Type: Article

References (46)

1. Posner M., Vermorken J.B. Induction therapy in the modern era of combined-modality therapy for locally advanced head and neck cancer. Semin Oncol 2008, 35:221-228.
2. Specenier P.M., Vermorken J.B. Neoadjuvant chemotherapy in head and neck cancer: should it be revisited?. Cancer Lett 2007, 256:166-177.
3. Ensley J.F., Jacobs J.R., Weaver A., et al. Correlation between response to cisplatinum-combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck. Cancer 1984, 54:811-814.
4. Lee W.C., Chavez Y.E., Baker T., et al. Economic burden of heart failure: a summary of recent literature. Heart Lung 2004, 33:362-371.
5. Fury M.G., Shah J.P. Induction chemotherapy in the management of head and neck cancer. J Surg Oncol 2010, 101:292-298.
6. Minn H., Lapela M., Klemi P.J., et al. Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer. J Nucl Med 1997, 38:1907-1911.
7. Schwartz D.L., Rajendran J., Yueh B., et al. FDG-PET prediction of head and neck squamous cell cancer outcomes. Arch Otolaryngol Head Neck Surg 2004, 130:1361-1367.
8. Hermans R., Meijerink M., Van den Bogaert W., et al. Tumor perfusion rate determined noninvasively by dynamic computed tomography predicts outcome in head-and-neck cancer after radiotherapy. Int J Radiat Oncol Biol Phys 2003, 57:1351-1356.
9. Gandhi D., Hoeffner E.G., Carlos R.C., et al. Computed tomography perfusion of squamous cell carcinoma of the upper aerodigestive tract. Initial results. J Comput Assist Tomogr 2003, 27:687-693.
10. Maldonado X., Alonso J., Giralt J., et al. 31Phosphorus magnetic resonance spectroscopy in the assessment of head and neck tumors. Int J Radiat Oncol Biol Phys 1998, 40:309-312.
11. Shukla-Dave A., Poptani H., Loevner L.A., et al. Prediction of treatment response of head and neck cancers with P-31 MR spectroscopy from pretreatment relative phosphomonoester levels. Acad Radiol 2002, 9:688-694.
12. Bezabeh T., Odlum O., Nason R., et al. Prediction of treatment response in head and neck cancer by magnetic resonance spectroscopy. AJNR Am J Neuroradiol 2005, 26:2108-2113.
13. Kim S., Loevner L.A., Quon H., et al. Prediction of response to chemoradiation therapy in squamous cell carcinomas of the head and neck using dynamic contrast-enhanced MR imaging. AJNR Am J Neuroradiol 2010, 31:262-268.
14. Gupta R.K., Sinha U., Cloughesy T.F., et al. Inverse correlation between choline magnetic resonance spectroscopy signal intensity and the apparent diffusion coefficient in human glioma. Magn Reson Med 1999, 41:2-7.
15. Guo A.C., Cummings T.J., Dash R.C., et al. Lymphomas and high-grade astrocytomas: comparison of water diffusibility and histologic characteristics. Radiology 2002, 224:177-183.
16. Zhao M., Pipe J.G., Bonnett J., et al. Early detection of treatment response by diffusion-weighted 1H-NMR spectroscopy in a murine tumour in vivo. Br J Cancer 1996, 73:61-64.
17. Chenevert T.L., McKeever P.E., Ross B.D. Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging. Clin Cancer Res 1997, 3:1457-1466.
18. Poptani H., Puumalainen A.M., Grohn O.H., et al. Monitoring thymidine kinase and ganciclovir-induced changes in rat malignant glioma in vivo by nuclear magnetic resonance imaging. Cancer Gene Ther 1998, 5:101-109.
19. Kauppinen R.A. Monitoring cytotoxic tumour treatment response by diffusion magnetic resonance imaging and proton spectroscopy. NMR Biomed 2002, 15:6-17.
20. Hamstra D.A., Lee K.C., Moffat B.A., et al. Diffusion magnetic resonance imaging: an imaging treatment response biomarker to chemoradiotherapy in a mouse model of squamous cell cancer of the head and neck. Transl Oncol 2008, 1:187-194.
21. Sumi M., Sakihama N., Sumi T., et al. Discrimination of metastatic cervical lymph nodes with diffusion-weighted MR imaging in patients with head and neck cancer. AJNR Am J Neuroradiol 2003, 24:1627-1634.
22. Wang J., Takashima S., Takayama F., et al. Head and neck lesions: characterization with diffusion-weighted echo-planar MR imaging. Radiology 2001, 220:621-630.
23. Srinivasan A., Dvorak R., Perni K., et al. Differentiation of benign and malignant pathology in the head and neck using 3T apparent diffusion coefficient values: early experience. AJNR Am J Neuroradiol 2008, 29:40-44.
24. Razek A.A., Megahed A.S., Denewer A., et al. Role of diffusion-weighted magnetic resonance imaging in differentiation between the viable and necrotic parts of head and neck tumors. Acta Radiol 2008, 49:364-370.
25. Vandecaveye V., De Keyzer F., Nuyts S., et al. Detection of head and neck squamous cell carcinoma with diffusion weighted MRI after (chemo)radiotherapy: correlation between radiologic and histopathologic findings. Int J Radiat Oncol Biol Phys 2007, 67:960-971.
26. Abdel Razek A.A., Kandeel A.Y., Soliman N., et al. Role of diffusion-weighted echo-planar MR imaging in differentiation of residual or recurrent head and neck tumors and posttreatment changes. AJNR Am J Neuroradiol 2007, 28:1146-1152.
27. Kim S., Loevner L., Quon H., et al. Diffusion-weighted magnetic resonance imaging for predicting and detecting early response to chemoradiation therapy of squamous cell carcinomas of the head and neck. Clin Cancer Res 2009, 15:986-994.
28. Kato H., Kanematsu M., Tanaka O., et al. Head and neck squamous cell carcinoma: usefulness of diffusion-weighted MR imaging in the prediction of a neoadjuvant therapeutic effect. Eur Radiol 2009, 19:103-109.
29. King A.D., Mo F.K., Yu K.H., et al. Squamous cell carcinoma of the head and neck: diffusion-weighted MR imaging for prediction and monitoring of treatment response. Eur Radiol 2010, 20:2213-2220.
30. Vandecaveye V., Dirix P., De Keyzer F., et al. Predictive value of diffusion-weighted magnetic resonance imaging during chemoradiotherapy for head and neck squamous cell carcinoma. Eur Radiol 2010, 20:1703-1714.
31. Garden A.S., Asper J.A., Morrison W.H., et al. Is concurrent chemoradiation the treatment of choice for all patients with stage III or IV head and neck carcinoma?. Cancer 2004, 100:1171-1178.
32. Denis F., Garaud P., Bardet E., et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004, 22:69-76.
33. Galons J.P., Altbach M.I., Paine-Murrieta G.D., et al. Early increases in breast tumor xenograft water mobility in response to paclitaxel therapy detected by non-invasive diffusion magnetic resonance imaging. Neoplasia 1999, 1:113-117.
34. Sharma U., Danishad K.K., Seenu V., et al. Longitudinal study of the assessment by MRI and diffusion-weighted imaging of tumor response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. NMR Biomed 2009, 22:104-113.
35. Yoshida S., Koga F., Kawakami S., et al. Initial experience of diffusion-weighted magnetic resonance imaging to assess therapeutic response to induction chemoradiotherapy against muscle-invasive bladder cancer. Urology 2010, 75:387-391.
36. Chepeha D.B., Sacco A.G., Oxford L.E., et al. Advanced squamous cell carcinoma of the oropharynx: efficacy of positron emission tomography and computed tomography for determining primary tumor response during induction chemotherapy. Head Neck 2009, 31:452-460.
37. Chu E., DeVita V.T. Principles of medical oncology. Cancer: Principles & Practice of Oncology 2005, 296-306. Lippincott Williams & Wilkins, Philadelphia, PA. V.T. DeVita, S. Hellman, S.A. Rosenberg (Eds.).
38. Larocque M.P., Syme A., Yahya A., et al. Monitoring T2 and ADC at 9.4 T following fractionated external beam radiation therapy in a mouse model. Phys Med Biol 2010, 55:1381-1393.
39. Larocque M.P., Syme A., Yahya A., et al. Temporal and dose dependence of T2 and ADC at 9.4 T in a mouse model following single fraction radiation therapy. Med Phys 2009, 36:2948-2954.
40. Madhu B., Waterton J.C., Griffiths J.R., et al. The response of RIF-1 fibrosarcomas to the vascular-disrupting agent ZD6126 assessed by in vivo and ex vivo 1H magnetic resonance spectroscopy. Neoplasia 2006, 8:560-567.
41. Knegjens J.L., Hauptmann M., Pameijer F.A., et al. Tumor volume as prognostic factor in chemoradiation for advanced head and neck cancer. Head Neck 2011, 33:375-382.
42. Brenner D.J. Dose, volume, and tumor-control predictions in radiotherapy. Int J Radiat Oncol Biol Phys 1993, 26:171-179.
43. Bentzen S.M., Ruifrok A.C., Thames H.D. Repair capacity and kinetics for human mucosa and epithelial tumors in the head and neck: clinical data on the effect of changing the time interval between multiple fractions per day in radiotherapy. Radiother Oncol 1996, 38:89-101.
44. Dubben H.H., Thames H.D., Beck-Bornholdt H.P. Tumor volume: a basic and specific response predictor in radiotherapy. Radiother Oncol 1998, 47:167-174.
45. Wendt T.G., Bank P. Prognostic factors in squamous cell carcinoma of the head and neck. Onkologie 2002, 25:208-212.
46. Forastiere A.A., Ang K., Brizel D., et al. Head and neck cancers. J Natl Compr Canc Netw 2005, 3:316-391.